Previous 10 | Next 10 |
Meeting and webcast scheduled for Thursday, April 11 in New York City CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 4, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announce...
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 3, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will present at the 18th Annual Needham Healthcare Conference. T...
- Clinical data highlight potential utility of T cell clonality as a predictive and prognostic biomarker of pelareorep therapy - - Using pelareorep in advance of the checkpoint inhibitor Keytruda® safely primes the immune system to target cancer cells in pancreatic cancer patients ...
- Combination Synergistic Even in Cells That Have Developed Resistance to Bortezomib - Article Published in the March 12 Edition of the Journal Blood Advances CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / March 28, 2019 / Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), cu...
I have been studying what effect uplisting has on the stock price of individual stocks. My first article concluded that a profit exceeding 25% was available in 65% of stocks that had uplisted during 2015 but that profit evaporated within the first year after uplisting. Only 10% of these same...
Oncolytics Biotech Inc. (ONCY) Q4 2018 Results Earnings Conference Call March 08, 2019, 08:30 AM ET Company Participants Michael Moore - VP of IR & Corporate Communications Matthew Coffey - President, CEO Kirk Look - CFO Conference Call Participants Wangzhi Li - Ladenbu...
Oncolytics Biotech (NASDAQ: ONCY ): FY GAAP EPS of -C$1.06. More news on: Oncolytics Biotech Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Recent biomarker data identifies a simple blood test that may predict clinical response to pelareorep - - AWARE-1 window of opportunity study in breast cancer to begin enrollment in the coming weeks with data expected in the second half of 2019 - - Combination stu...
CALGARY, AB and SAN DIEGO, CA / March 1, 2019 / Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call and live webcast for Analysts and Institutional I...
Data identifies a simple blood test that predicts clinical response to pelareorep CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 27, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus,...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONCY Stock Symbol:
NASDAQ Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Canada NewsWire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report ove...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Canada NewsWire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast ca...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...